Patents by Inventor Sunil Bhakta
Sunil Bhakta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11873330Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.Type: GrantFiled: February 11, 2020Date of Patent: January 16, 2024Assignee: Genentech, Inc.Inventors: Sunil Bhakta, Jagath R. Junutula
-
Publication number: 20230130874Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.Type: ApplicationFiled: May 13, 2022Publication date: April 27, 2023Applicant: Genentech, Inc.Inventors: Sunil Bhakta, Hans Erickson, Jagath R. Junutula, Katherine Kozak, Rachana Ohri, Thomas Harden Pillow
-
Publication number: 20200339664Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.Type: ApplicationFiled: February 11, 2020Publication date: October 29, 2020Applicant: Genentech, Inc.Inventors: Sunil Bhakta, Jagath R. Junutula
-
Patent number: 10604557Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.Type: GrantFiled: November 21, 2016Date of Patent: March 31, 2020Assignee: Genentech, Inc.Inventors: Sunil Bhakta, Jagath R. Junutula
-
Publication number: 20200017601Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.Type: ApplicationFiled: March 14, 2019Publication date: January 16, 2020Applicant: Genentech, Inc.Inventors: Sunil BHAKTA, Hans ERICKSON, Jagath R. JUNUTULA, Katherine KOZAK, Rachana OHRI, Thomas PILLOW
-
Patent number: 10077318Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.Type: GrantFiled: September 11, 2015Date of Patent: September 18, 2018Assignee: Genentech, Inc.Inventors: Sunil Bhakta, Hans Erickson, Jagath R. Junutula, Katherine Kozak, Rachana Ohri, Thomas Pillow
-
Publication number: 20170260253Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.Type: ApplicationFiled: November 21, 2016Publication date: September 14, 2017Applicant: Genentech, Inc.Inventors: Sunil Bhakta, Jagath R. Junutula
-
Publication number: 20170129963Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: September 15, 2016Publication date: May 11, 2017Applicant: Genentech, Inc.Inventors: Sunil Bhakta, Meredith C. Hazen, Jo-Anne S. Hongo, Jagath R. Junutula
-
Patent number: 9580514Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.Type: GrantFiled: March 14, 2013Date of Patent: February 28, 2017Assignee: Genentech, Inc.Inventors: Sunil Bhakta, Meredith Hazen, Jo-Anne S Hongo, Jagath R Junutula, Isidro Hotzel, Yonglei Shang, Shang-Fan Yu
-
Publication number: 20160130358Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.Type: ApplicationFiled: September 11, 2015Publication date: May 12, 2016Applicant: Genentech, Inc.Inventors: Sunil BHAKTA, Hans ERICKSON, Jagath R. JUNUTULA, Katherine KOZAK, Rachana OHRI, Thomas PILLOW
-
Publication number: 20150098946Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.Type: ApplicationFiled: March 14, 2013Publication date: April 9, 2015Applicant: Genentech, Inc.Inventors: Sunil Bhakta, Meredith Hazen, Jo-Anne S Hongo, Jagath R Junutula, Isidro Hotzel, Yonglei Shang, Shang-Fan Yu
-
Patent number: 9000130Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.Type: GrantFiled: June 7, 2011Date of Patent: April 7, 2015Assignee: Genentech, Inc.Inventors: Sunil Bhakta, Jagath R. Junutula
-
Publication number: 20140288280Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.Type: ApplicationFiled: February 20, 2014Publication date: September 25, 2014Applicant: Genentech, Inc.Inventors: Sunil Bhakta, Jagath R. Junutula
-
Publication number: 20110301334Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.Type: ApplicationFiled: June 7, 2011Publication date: December 8, 2011Inventors: Sunil Bhakta, Jagath R. Junutula
-
Patent number: 7687606Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: December 19, 2006Date of Patent: March 30, 2010Assignee: AstraZeneca ABInventors: Jean M. Gudas, Mary Haak-Frendscho, Orit Foord, Meina L. Liang, Kiran Ahluwalia, Sunil Bhakta
-
Patent number: 7482434Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: December 19, 2006Date of Patent: January 27, 2009Assignee: AstraZeneca ABInventors: Jean M. Gudas, Mary Haak-Frendscho, Orit Foord, Meina L. Liang, Kiran Ahluwalia, Sunil Bhakta
-
Publication number: 20070128112Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: December 19, 2006Publication date: June 7, 2007Inventors: Jean Gudas, Mary Haak-Frendscho, Orit Foord, Meina Liang, Kiran Ahluwalia, Sunil Bhakta
-
Publication number: 20070116708Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: December 19, 2006Publication date: May 24, 2007Inventors: Jean Gudas, Mary Haak-Frendscho, Orit Foord, Meina Liang, Kiran Ahluwalia, Sunil Bhakta
-
Patent number: 7202343Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: August 19, 2003Date of Patent: April 10, 2007Assignee: Abgenix, Inc.Inventors: Jean M. Gudas, Mary Haak-Frendscho, Orit Foord, Meina L. Liang, Kiran Ahluwalia, Sunil Bhakta
-
Publication number: 20050058639Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: August 19, 2003Publication date: March 17, 2005Inventors: Jean Gudas, Mary Haak-Frendscho, Orit Foord, Meina Liang, Kiran Ahluwalia, Sunil Bhakta